PMID- 26707044
OWN - NLM
STAT- MEDLINE
DCOM- 20160421
LR  - 20181202
IS  - 0172-780X (Print)
IS  - 0172-780X (Linking)
VI  - 36
IP  - 5
DP  - 2015
TI  - Increased expression of activation antigens on CD8+ T lymphocytes in Myalgic 
      Encephalomyelitis/chronic fatigue syndrome: inverse associations with lowered 
      CD19+ expression and CD4+/CD8+ ratio, but no associations with (auto)immune, 
      leaky gut, oxidative and nitrosative stress biomarkers.
PG  - 439-46
AB  - BACKGROUND: There is now evidence that specific subgroups of patients with 
      Myalgic Encephalomyelitis / chronic fatigue syndrome (ME/CFS) suffer from a 
      neuro-psychiatric-immune disorder. This study was carried out to delineate the 
      expression of the activation markers CD38 and human leukocyte antigen (HLA) DR on 
      CD4+ and CD8+ peripheral blood lymphocytes in ME/CFS. METHODS: Proportions and 
      absolute numbers of peripheral lymphocytes expressing CD3+, CD19+, CD4+, CD8+, 
      CD38+ and HLA-DR+ were measured in ME/CFS (n=139), chronic fatigue (CF, n=65) and 
      normal controls (n=40). RESULTS: The proportions of CD3+, CD8+, CD8+CD38+ and 
      CD8+HLA-DR+ were significantly higher in ME/CFS patients than controls, while 
      CD38+, CD8+CD38+, CD8+HLA-DR+ and CD38+HLA-DR+ were significantly higher in 
      ME/CFS than CF. The percentage of CD19+ cells and the CD4+/CD8+ ratio were 
      significantly lower in ME/CFS and CF than in controls. There were highly 
      significant inverse correlations between the increased expression of CD38+, 
      especially that of CD8+CD38+, and the lowered CD4+/CD8+ ratio and CD19+ 
      expression. There were no significant associations between the flow cytometric 
      results and severity or duration of illness and peripheral blood biomarkers of 
      oxidative and nitrosative stress (O&NS, i.e. IgM responses to O&N modified 
      epitopes), leaky gut (IgM or IgA responses to LPS of gut commensal bacteria), 
      cytokines (interleukin-1, tumor necrosis factor-alpha), neopterin, lysozyme and 
      autoimmune responses to serotonin. CONCLUSIONS: The results support that a) 
      increased CD38 and HLA-DR expression on CD8+ T cells are biomarkers of ME/CFS; b) 
      increased CD38 antigen expression may contribute to suppression of the CD4+/CD8+ 
      ratio and CD19+ expression; c) there are different immune subgroups of ME/CFS 
      patients, e.g. increased CD8+ activation marker expression versus inflammation or 
      O&NS processes; and d) viral infections or reactivation may play a role in a some 
      ME/CFS patients.
FAU - Maes, Michael
AU  - Maes M
AD  - IMPACT Strategic Research Centre, Deakin University, School of Medicine and 
      Barwon Health, Geelong, VIC, Australia.
FAU - Bosmans, Eugene
AU  - Bosmans E
AD  - AML Laboratories, Antwerp, Belgium.
FAU - Kubera, Marta
AU  - Kubera M
AD  - Department of Experimental Neuroendocrinology, Institute of Pharmacology, Polish 
      Academy of Sciences, Krakow, Poland.
LA  - eng
PT  - Journal Article
PL  - Sweden
TA  - Neuro Endocrinol Lett
JT  - Neuro endocrinology letters
JID - 8008373
RN  - 0 (Antigens, CD19)
RN  - 0 (Biomarkers)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interleukin-1)
RN  - 0 (TNF protein, human)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 670-65-5 (Neopterin)
RN  - EC 3.2.1.17 (Muramidase)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
SB  - IM
MH  - ADP-ribosyl Cyclase 1/*immunology
MH  - Adult
MH  - Antigens, CD19/immunology
MH  - Biomarkers
MH  - CD4-CD8 Ratio
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - Fatigue Syndrome, Chronic/*immunology
MH  - Female
MH  - HLA-DR Antigens/*immunology
MH  - Humans
MH  - Interleukin-1/immunology
MH  - Intestinal Mucosa/metabolism
MH  - Intestines/immunology
MH  - Male
MH  - Middle Aged
MH  - Muramidase/immunology
MH  - Neopterin/immunology
MH  - Nitrosation/immunology
MH  - Oxidative Stress/immunology
MH  - Permeability
MH  - Tumor Necrosis Factor-alpha/immunology
EDAT- 2015/12/29 06:00
MHDA- 2016/04/22 06:00
CRDT- 2015/12/29 06:00
PHST- 2015/08/12 00:00 [received]
PHST- 2015/09/03 00:00 [accepted]
PHST- 2015/12/29 06:00 [entrez]
PHST- 2015/12/29 06:00 [pubmed]
PHST- 2016/04/22 06:00 [medline]
AID - NEL360515A05 [pii]
PST - ppublish
SO  - Neuro Endocrinol Lett. 2015;36(5):439-46.